Abstract | BACKGROUND: METHODS: RESULTS: Seven patients were excluded, leaving a total of 31 included in the trial. Eleven had a score of 3, 17 a score of 2, and 3 a score of 1. The degree of gingival hyperplasia was unrelated to the dose and levels of cyclosporin. Gingival hyperplasia improved in all patients (P < 0.001, Friedman test). The degree of improvement was better when the degree of hyperplasia was lower. In 27 patients gingival hyperplasia remained absent 6 months later, 3 patients required a second course of treatment, and another required gingival surgery. Gingival bleeding, present in 28 patients when diagnosed, disappeared in all cases in 2.2 +/- 1.2 (1-7) days. No adverse effects were observed. Cyclosporin, serum creatinine, and ALT levels were not affected by treatment. CONCLUSIONS:
|
Authors | E Gómez, M Sánchez-Nuñez, J E Sánchez, C Corte, S Aguado, C Portal, J Baltar, J Alvarez-Grande |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 12
Issue 12
Pg. 2694-7
(Dec 1997)
ISSN: 0931-0509 [Print] England |
PMID | 9430874
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Immunosuppressive Agents
- Azithromycin
- Cyclosporine
|
Topics |
- Adult
- Aged
- Anti-Bacterial Agents
(therapeutic use)
- Azithromycin
(therapeutic use)
- Cyclosporine
(adverse effects, therapeutic use)
- Female
- Gingival Hyperplasia
(chemically induced, drug therapy, pathology)
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Kidney Transplantation
- Male
- Middle Aged
- Postoperative Care
|